We have revised upwards the forecast for Canada s pharmaceutical market following the incorporation of newly available industry and macroeconomic data into our model. The current market size is slightly larger (CAD--.-bn (USD--.-bn) We have revised upwards the forecast for Canada s pharmaceutical market following the incorporation of newly available industry and macroeconomic data into our model. previously), and the projected expenditure trajectory is marginally higher (---year compound annual growth rate of -.- versus -.- previously). In August ---- ProMetic Life Sciences entered a binding agreement for the acquisition of Telesta Therapeutics. ...Completion of the acquisition is expected to close in early November ---- and is subject to the approval of Telesta s shareholders and other closing conditions.
...In February ----, the Canadian government s Patented Medicine Prices Review Board (PMPRB) released a report, entitled Generics---, which found that there were significant declines in domestic generic price levels between ---- and ----. Canadian generic prices fell, on average, by -- , exceeding the generic drug price declines in all other foreign markets analysed. Relative to their brand-name counterparts, average generic prices in Canada declined from -- to -- over this time period. Pharmaceutical Market Forecast --------- (---------) Pharmaceutical sales, USDbn Pharmaceutical sales constant exchange rate, USDbn Pharmaceutical sales, of GDP ---- ---- ---- ---- ---- ----f ----f ----f ----f ----f ----f ----f ----f ----f ----f - -- -- -- -.- -.- -.- -.- f = BMI forecast. Relative to their brand-name counterparts, average generic prices in Canada declined from -- to -- over this time period. ...Pharmaceutical Market Forecast --------- (---------) Pharmaceutical sales, USDbn Pharmaceutical sales constant exchange rate, USDbn Pharmaceutical sales, of GDP ---- ---- ---- ---- ---- ----f ----f ----f ----f ----f ----f ----f ----f ----f ----f - -- -- -- -.- -.- -.- -.- f = BMI forecast.
...Government cost-cutting measures have served to slow the rate of patented market growth. Relations with both multinational drugmakers and the US FDA have weakened notably over the last few years, as a result of the growth in the re-import of prescription drugs to the US. ...Government cost-cutting measures have served to slow the rate of patented market growth. Relations with both multinational drugmakers and the US FDA have weakened notably over the last few years, as a result of the growth in the re-import of prescription drugs to the US. The introduction of the Medicare system in the US has reduced exports from Canadian pharmacies. ...